Recruiting

Observational Study

Sponsor:

National Center for Genome Resources

Code:

NCT00258869

Conditions

Sepsis

Septicemia

Sepsis Syndrome

Shock, Septic

Community Acquired Pneumonia

Eligibility Criteria

Sex: All

Age: 6+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

We propose to develop novel diagnostic tests for severe sepsis and community acquired pneumonia (CAP). This program, entitled Community Acquired Pneumonia \& Sepsis Outcome Diagnostics (CAPSOD), is a multidisciplinary collaboration involving investigators at six organizations: NCGR; Duke University Medical Center, Durham, NC; Henry Ford Hospital, Detroit, MI; Eli Lilly and Company, Indianapolis, IN; Indiana Centers for Applied Protein Sciences, Indianapolis, IN; and ProSanos Corp., La Jolla, CA.

In the United States, Community Acquired Pneumonia is the sixth leading cause of death and the number one cause of death from infectious diseases. Of the 5.6 million annual cases of CAP, 1.1 million require hospitalization for intensive therapy. Sepsis, commonly known as blood poisoning or bloodstream infection, is the tenth leading cause of death in the US and the number one cause of death in non-cardiac intensive care units. Incidence of sepsis is increasing by 9% each year and mortality rates vary between 25 and 50%. Cost to the US healthcare system exceeds $20 billion each year.

In patients with suspected sepsis or early CAP, rapid identification of patients who will develop severe sepsis or CAP is critical for effective management and positive outcome. The CAPSOD study is designed to identify novel tests for early diagnosis of severe sepsis and CAP. When performed in patients at the earliest stages of disease, these tests will have prognostic value, rapidly identifying those who will have poor outcomes or complicated courses.

CAPSOD will prospectively enroll patients with sepsis and CAP at Duke University Medical Center and Henry Ford Hospital. The study will use advanced bioinformatic, metabolomic, proteomic and mRNA sequencing technologies to identify specific protein changes, or biomarkers, in patient blood samples that predict outcome in sepsis and CAP. Development of biomarker-based tests will permit patient selection for appropriate disposition, such as the intensive care unit, and use of intensive medical therapies, thereby reducing mortality and increasing effectiveness of resource allocation.

Conditions

Sepsis

Septicemia

Sepsis Syndrome

Shock, Septic

Community Acquired Pneumonia

Study ID

NCT00258869

Start date

Dec, 2005

Status verified date

Jan, 2009

Completion date

Jul, 2010

Anticipated

Primary completion date

Jul, 2010

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 6+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patient has known or acute infection or suspected infection AND patient must meet at least 2 of the following 4 criteria to be enrolled

1. A core temperature of >= 38°C (100.4°F) or <= 36°C (96.8°F)
2. Patients > 18 years of age, Heart rate of >= 90 beats/min Patients 13-18 years of age, Heart rate of >= 110 beats/min Patients 6-12 years of age, Heart rate of >= 130 beats/min
3. Patients > 18 years of age, Respiratory rate of >= 20 breaths/min Patients 13-18 years of age, Respiratory rate of >= 14 breaths/min Patients 6-12 years of age, Respiratory rate of >= 18 breaths/min OR PaCO2 of <= 32 mm Hg OR Use of Mechanical Ventilation for an acute respiratory process
4. Patients > 18 years of age, White cell count >= 12,000/mm3 or <= 4,000/mm3 Patients 13-18 years of age, White cell count >= 11,000/mm3 or <= 4,500/mm3 Patients 6-12 years of age, White cell count >= 13,500/mm3 or <= 4,500/mm3 OR A differential count showing > 10% immature neutrophils

Exclusion Criteria:

1. Patient is less than 6 years of age.
2. Patient is not expected to survive 28 days because of uncorrectable medical condition (apart from pneumonia or sepsis), such as poorly controlled neoplasm or other end-stage disease, or patient has active DNR order
3. Human immunodeficiency virus (HIV) infection with a last known CD4 count of <50 mm3
4. Acute presence of a cerebral vascular event, active gastrointestinal hemorrhage, seizure (acute episode), drug overdose, burn injury, trauma
5. Patient is pregnant

Study Design

Enrollment

1200 participants

Anticipated

Interventions and Outcome Measures

Arms

1

Emergency department patients with sepsis

Primary outcome measure

  • Death [ Time Frame: Day 3 ]
  • Septic Shock [ Time Frame: Day 3 ]
  • Severe Sepsis [ Time Frame: Day 3 ]

Central Contacts and Locations

Central contacts

Stephen F Kingsmore, MB ChB BAO

505 995 4466sfk@ncgr.org

Locations

Henry Ford Hospital

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Emanuel P Rivers, MD

800-436-7936erivers1@hfhs.org

Principal Investigator:

Emanuel P Rivers, MD

Duke University Medical Center

Recruiting

Durham, North Carolina, United States, 27710

Contacts

Principal Investigator:

Vance G Fowler, MD

Durham VA Medical Center

Recruiting

Durham, North Carolina, United States, 27710

Contacts

Principal Investigator:

Christopher Woods, MD

More Information

Sponsor

National Center for Genome Resources

Last update posted

Nov 9, 2010

Last verified

Jan, 2009

Keywords

  • prospective studies
  • biological assay
  • body weights and measures
  • chemistry, analytical
  • microchip analytical procedures
  • spectrum analysis, mass
  • molecular diagnostic techniques
  • microbiological techniques
  • drug administration schedule
  • data collection
  • statistics
  • gene expression profiling
  • sequence analysis
  • human experimentation
  • immunoassay
  • Trauma severity indices
  • Glasgow Coma score
  • Outcome assessment
  • mortality
  • computer models
  • decision modeling
  • linear models
  • logistic models
  • immunologic model
  • mathematical model
  • non-linear models
  • early diagnosis
  • diagnosis, computer assisted
  • medical informatics
  • prognosis
  • registries
  • computational biology
  • systems biology

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by National Center for Genome Resources on 2010-11-09.